SCHEDULE: Invus Group Discloses 9.99% Stake in Solid Biosciences

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 10,066,682 shares, representing 9.99% of Solid Biosciences Inc.'s outstanding common stock as of March 31, 2026.

Summary

• Invus Public Equities, L.P. and its affiliated entities (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership of 10,066,682 shares of Solid Biosciences Inc. common stock.
• This holding represents 9.99% of the company's issued and outstanding shares as of March 31, 2026.
• The reported shares include 7,690,405 directly held shares and 2,376,277 shares issuable upon exercise of warrants.
• The Reporting Persons are Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Raymond Debbane.
• The filing specifies a Beneficial Ownership Limitation, preventing the exercise of warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it is a routine disclosure of a significant ownership stake and does not inherently signal positive or negative performance for the company.

Positives

• Significant stake held by Invus Group, potentially indicating confidence in Solid Biosciences' long-term prospects.
• The reporting is current as of March 31, 2026, providing up-to-date information on major shareholding.

Negatives

• The Beneficial Ownership Limitation on warrants restricts the immediate conversion of all held warrants into shares, capping the effective ownership at 9.99%.

Risks

• The Beneficial Ownership Limitation could prevent the Reporting Persons from increasing their stake beyond 9.99% without a 61-day notice period to the issuer.
• Potential for future changes in beneficial ownership, as the limitation can be adjusted by the holder with notice.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders in the biotechnology sector, reflecting active portfolio management and strategic positioning within companies focused on drug development and therapeutic advancements.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant ownership block, which can influence market perception and trading dynamics.
• Management and Board of Directors: The substantial stake held by Invus Group may warrant engagement and communication regarding the company's strategic direction.

Next Steps

• The Reporting Persons may adjust their holdings based on market conditions and their investment strategies.
• The Beneficial Ownership Limitation can be changed by the holder upon 61 days' notice to the Issuer.

Key Dates

Keywords

Solid Biosciences, Schedule 13G, Invus Group, Beneficial Ownership, Shareholder, Investment, Warrants, SEC Filing